title: Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line.
abstract: With the increasing use of inducers of cellular differentiation in the treatment of leukaemia, it is essential to understand the relationship between differentiation and the expression of the multidrug resistance. Using the K562 human leukaemia cell line and its multidrug resistant subline K562/E15B, differentiation was examined along two different pathways, megakaryocyte in response to treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA), and erythroid in response to treatment with sodium butyrate, in the same cell line. P-glycoprotein expression was increased in the multidrug resistant K562/E15B subline, but not induced in the parental K562 cell line. However, both treatments conferred a different phenotype on the drug resistant subline. TPA treatment caused an increase in P-glycoprotein, increased drug resistance and decreased rhodamine-123 accumulation which was verapamil sensitive, demonstrating that TPA induced a fully functional P-glycoprotein. However, sodium butyrate treatment caused an increase in P-glycoprotein without increased drug resistance or without decreased rhodamine-123 accumulation suggesting that the P-glycoprotein induced by sodium butyrate was nonfunctional. These results stress the importance of examining not only the expression of P-glycoprotein in cells, but also the function of the P-glycoprotein induced.
authors.affiliation: Neurobiology Unit, University of Technology, Sydney, NSW, Australia.
authors.forename: D C
authors.initials: DC
authors.lastname: Marks
authors.forename: M W
authors.initials: MW
authors.lastname: Davey
authors.forename: R A
authors.initials: RA
authors.lastname: Davey
authors.forename: A D
authors.initials: AD
authors.lastname: Kidman
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002454:Cell Differentiation; D002470:Cell Survival; D003078:Colchicine / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D015251:Epirubicin / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D010641:Phenotype; D020112:Rhodamine 123; D012235:Rhodamines; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014700:Verapamil / Q000494:pharmacology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002087:Butyrates; D012235:Rhodamines; D020148:Butyric Acid; D020112:Rhodamine 123; D015251:Epirubicin; D014700:Verapamil; D013755:Tetradecanoylphorbol Acetate; D003078:Colchicine